Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study

por Nakamoto, Shogo, Watanabe, Junichiro, Ohtani, Shoichiro, Morita, Satoshi, Ikeda, Masahiko
Publicado 2021

Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study

por Nakamoto, Shogo, Watanabe, Junichiro, Ohtani, Shoichiro, Morita, Satoshi, Ikeda, Masahiko
Publicado 2022

Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer

por Nakamoto, Shogo, Ikeda, Masahiko, Kubo, Shinichiro, Yamamoto, Mari, Yamashita, Tetsumasa, Notsu, Akifumi
Publicado 2021

Imaging features of breast cancer with marked hemosiderin deposition: A case report

por Harada, Taiyo L., Nakashima, Kazuaki, Uematsu, Takayoshi, Sugino, Takashi, Nishimura, Seiichirou, Takahashi, Kaoru, Tadokoro, Yukiko, Hayashi, Tomomi, Watanabe, Junichiro, Nakamoto, Shogo
Publicado 2019